Analysts Expect American Vanguard Corp. (AVD) Will Post Quarterly Sales of $107.35 Million

Equities research analysts expect American Vanguard Corp. (NYSE:AVD) to report sales of $107.35 million for the current quarter, Zacks reports. Two analysts have issued estimates for American Vanguard’s earnings, with estimates ranging from $103.30 million to $111.40 million. American Vanguard posted sales of $70.67 million during the same quarter last year, which suggests a positive year-over-year growth rate of 51.9%. The company is scheduled to issue its next earnings report on Thursday, May 3rd.

On average, analysts expect that American Vanguard will report full year sales of $107.35 million for the current fiscal year, with estimates ranging from $463.20 million to $478.20 million. For the next year, analysts forecast that the company will post sales of $499.35 million per share, with estimates ranging from $481.70 million to $517.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow American Vanguard.

How to Become a New Pot Stock Millionaire

American Vanguard (NYSE:AVD) last issued its earnings results on Monday, March 12th. The basic materials company reported $0.17 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.17. American Vanguard had a return on equity of 5.74% and a net margin of 5.70%. The business had revenue of $116.50 million during the quarter, compared to analyst estimates of $110.06 million. During the same quarter in the previous year, the firm earned $0.13 EPS. American Vanguard’s revenue was up 33.1% on a year-over-year basis.

A number of equities analysts have weighed in on AVD shares. Zacks Investment Research raised American Vanguard from a “sell” rating to a “hold” rating in a research report on Tuesday, January 2nd. Roth Capital restated a “buy” rating on shares of American Vanguard in a research note on Thursday, March 15th. Finally, ValuEngine upgraded American Vanguard from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company. American Vanguard currently has an average rating of “Hold” and a consensus target price of $25.33.

NYSE:AVD traded down $0.30 during mid-day trading on Wednesday, reaching $20.75. The company’s stock had a trading volume of 102,809 shares, compared to its average volume of 146,754. American Vanguard has a 12-month low of $15.20 and a 12-month high of $24.00. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.04 and a current ratio of 2.02. The firm has a market cap of $627.18, a price-to-earnings ratio of 36.40 and a beta of 1.19.

The company also recently declared a quarterly dividend, which will be paid on Friday, April 13th. Shareholders of record on Friday, March 30th will be paid a dividend of $0.02 per share. This is an increase from American Vanguard’s previous quarterly dividend of $0.02. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.39%. The ex-dividend date of this dividend is Wednesday, March 28th. American Vanguard’s payout ratio is currently 14.04%.

Institutional investors have recently added to or reduced their stakes in the business. Macquarie Group Ltd. bought a new stake in shares of American Vanguard during the 3rd quarter valued at about $141,000. Citadel Advisors LLC bought a new position in shares of American Vanguard during the 3rd quarter valued at approximately $227,000. MetLife Investment Advisors LLC bought a new position in shares of American Vanguard during the 4th quarter valued at approximately $293,000. BNP Paribas Arbitrage SA grew its stake in shares of American Vanguard by 58.5% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 14,294 shares of the basic materials company’s stock valued at $327,000 after acquiring an additional 5,275 shares during the period. Finally, Nordea Investment Management AB bought a new position in shares of American Vanguard during the 3rd quarter valued at approximately $403,000. Institutional investors and hedge funds own 76.80% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Analysts Expect American Vanguard Corp. (AVD) Will Post Quarterly Sales of $107.35 Million” was first published by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3338974/analysts-expect-american-vanguard-corp-avd-will-post-quarterly-sales-of-107-35-million.html.

About American Vanguard

American Vanguard Corporation operates as a holding company. The Company conducts its business through its subsidiaries, AMVAC Chemical Corporation (AMVAC), GemChem, Inc (GemChem), 2110 Davie Corporation (DAVIE), Quimica Amvac de Mexico SA de C.V. (AMVAC M), AMVAC Mexico Sociedad de Responsabilidad Limitada (AMVAC M Srl), AMVAC de Costa Rica Sociedad de Responsabilidad Limitada (AMVAC CR Srl), AMVAC Switzerland GmbH (AMVAC S), AMVAC do Brasil Representacoes Ltda (AMVAC B), AMVAC C.V.

Get a free copy of the Zacks research report on American Vanguard (AVD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for American Vanguard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Vanguard and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Universal Currency  Market Cap Tops $6.19 Million
Universal Currency Market Cap Tops $6.19 Million
RHFCoin Trading 3% Higher  Over Last Week
RHFCoin Trading 3% Higher Over Last Week
HomeBlockCoin Achieves Market Capitalization of $80,948.00
HomeBlockCoin Achieves Market Capitalization of $80,948.00
Comparing Ensign Group  & Genesis HealthCare
Comparing Ensign Group & Genesis HealthCare
Contrasting Moelis & Company  & The Competition
Contrasting Moelis & Company & The Competition
Financial Comparison: Intrexon  versus Sorrento Therapeutics
Financial Comparison: Intrexon versus Sorrento Therapeutics


Leave a Reply

© 2006-2018 Ticker Report. Google+.